• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Datavault AI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    3/19/26 8:12:57 AM ET
    $DVLT
    Semiconductors
    Technology
    Get the next $DVLT alert in real time by email
    false 0001682149 0001682149 2026-03-18 2026-03-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): March 18, 2026

     

    Datavault AI Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-38608   30-1135279
    (State of
    incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    One Commerce Square,

    2005 Market Street, Suite 2400,

    Philadelphia, PA

      19103
    (Address of Principal Executive Offices)   (Zip Code)

     

    (408)-627-4716

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former Name or former address if changed from last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.0001 per share   DVLT   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Datavault AI Inc., (the “Company”), DVLT Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and NYIAX, Inc. (“NYIAX”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated March 18, 2026. Pursuant to the provisions of the Merger Agreement, on the closing date (the “Closing Date”), (i) Merger Sub will merge with and into NYIAX (the “Merger”), the separate corporate existence of Merger Sub will cease and NYIAX will continue as the surviving company and a wholly owned subsidiary of the Company, and (ii) the Company will pay to NYIAX equity holders aggregate consideration (“Merger Consideration”) of 78,947,368 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

     

    Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), by virtue of the Merger and without any action on the part of the stockholders of NYIAX (the “Merger Partner Stockholders”), (i) each outstanding share of NYIAX’s common stock, par value $0.0001 per share (the “NYIAX Common Stock”), other than any shares of NYIAX Common Stock held in the treasury of NYIAX will be converted into the right to receive (i) a number of shares of Common Stock equal to the Exchange Ratio (as defined in ther Merger Agreement), or (ii) each share of NYIAX Common Stock held immediately prior to the Effective Time by a Merger Partner Stockholder that is an Unaccredited Investor (as defined in the Merger Agreement) will be converted into the right to receive the unaccredited investor cash consideration, which will be the higher of (i) price per share equal to the VWAP (as defined in the Merger Agreement) of the Common Stock for the five (5) consecutive Trading Days (as defined in the Merger Agreement) ending on the Trading Day immediately preceding the date of the Merger Agreement, or (ii) price per share equal to the VWAP of the Common Stock for the five (5) consecutive Trading Days ending on the Trading Day immediately preceding the Closing Date.

     

    Pursuant to the Merger Agreement, if the Company effects or announces an intent to effect a reverse stock split of the Common Stock at any time within one hundred twenty (120) days following the date of the Merger Agreement, then the Company will issue to the Merger Partner Stockholders, on a pro rata basis in accordance with their respective entitlements to the Merger Consideration, an aggregate of 10,000,000 duly authorized, validly issued, fully paid and nonassessable additional shares of Common Stock.

     

    Pursuant to the terms of the Merger Agreement, the Company has also agreed to appoint two new members to the board of directors of the Company (the “Board”), nominated by NYIAX and subject to such nominees being acceptable to the Company, effective as of the Closing Date.

     

    The Merger Agreement contains representations and warranties from both the Company and Merger Sub, on the one hand, and NYIAX, on the other hand, customary for a transaction of this nature. The Merger Agreement also contains customary covenants and agreements, including with respect to the operations of the business of NYIAX and the Company between the date of the Merger Agreement and Effective Time. The completion of the Merger will also be subject to closing conditions, customary for a transaction of this nature. NYIAX will be subject to customary “no-shop” restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide information to, and continue or participate in discussions and engage in negotiations with, third parties regarding any alternative acquisition proposals, subject to a customary “fiduciary out” provision that allows the Company, under certain specified circumstances and subject to other terms and conditions in the Merger Agreement, to provide information to, and continue or participate in discussions and engage in negotiations with, third parties with respect to an alternative acquisition proposal if the board of directors of NYIAX (the “NYIAX Board”) (or a committee thereof) determines in good faith (after consultation with its financial advisor and outside legal counsel) that such alternative acquisition proposal either constitutes a superior proposal or is reasonably likely to lead to a superior proposal, and the NYIAX Board (or a committee thereof) has determined in good faith (after consultation with its financial advisor and outside legal counsel) that the failure to take such actions could reasonably be expected to be inconsistent with its fiduciary duties pursuant to applicable law.

     

     

     

     

    Pursuant to the Merger Agreement if, at any time during the period beginning on the Closing Date and ending on the date that is twelve (12) months following the Closing Date, the Surviving Corporation (as defined in the Merger Agreement), or the Company, executed and announced a definitive commercial, strategic, joint venture, licensing, partnership, or other bona fide revenue-generating or value-enhancing agreement with a trading market (a “Trading Market Transaction”), approved by the Board, then the Company shall issue to the Merger Partner Stockholders, on a pro rata basis in accordance with their respective ownership immediately prior to the Effective Time, an aggregate of 13,000,000 duly authorized, validly issued, fully paid and nonassessable restricted shares of Common Stock (the “Earn-Out Shares”). In lieu thereof, each Unaccredited Investor shall be entitled to receive, with respect to each share of NYIAX Common Stock held immediately prior to the Effective Time, a cash payment equal to the higher of (i) price per share equal to the VWAP of the Common Stock for the five (5) consecutive Trading Days ending on the Trading Day immediately preceding the Closing Date, or (ii) price per share equal to the VWAP of the Common Stock for the five (5) consecutive Trading Days ending on the Trading Day immediately preceding the execution and announcement of Trading Market Transaction, without interest and subject to applicable tax withholding.

     

    From the closing and for a period of twelve (12) months thereafter, NYIAX has agreed to a special indemnity, pursuant to which NYIAX will indemnify, defend and hold harmless the Company, the Surviving Corporation from and against any and all Losses (as defined in the Merger Agreement) arising out of, relating to, or resulting from certain specific, enumerated claims, actions, suits, proceedings, investigations or demands against NYIAX set forth in the Merger Agreement, including any continuation, amendment, extension or escalation thereof. Any and all Losses for which indemnification is required under the Merger Agreement will be satisfied solely by a reduction in the number of Trading Market Transaction earn-out shares otherwise issuable to the Merger Partner Stockholders pursuant to Merger Agreement. In no event shall the aggregate number of Trading Market Transaction earn-out shares subject to reduction pursuant to the Merger Agreement exceed 5,000,000 shares of Common Stock.

     

    Pursuant to the Merger Agreement, the Company has agreed to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 (or, if the Company is not then eligible to use Form S-3, on Form S-1) (the “Resale Registration Statement”), within thirty (30) calendar days following the Closing Date, covering the resale of all shares of Common Stock issued to Merger Partner Stockholders as Merger Consideration pursuant to Merger Agreement. The Company shall use its commercially reasonable efforts to cause the Resale Registration Statement to be declared effective by the SEC as promptly as practicable after filing, and in no event later than the earlier of (i) sixty (60) calendar days following the Closing Date (or ninety (90) calendar days if the SEC reviews the Resale Registration Statement), and (ii) the fifth (5th) business day after the Company is notified by the SEC that the Resale Registration Statement will not be reviewed or is no longer subject to further review. The Earn-Out Shares will have similar registration rights upon issuance of such shares.

     

    The Merger Agreement contains customary termination rights for both the Company and Merger Sub, on the one hand, and NYIAX, on the other hand, including, among others, for failure to consummate the Merger within 90 days from the signing of the Merger Agreement.

     

    The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated herein by reference.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The disclosure required by this Item and included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The Merger Consideration have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

     

    The Merger Consideration has not been registered under the Securities Act, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The securities will be issued and were issued in reliance upon exemptions from registration under Section 4(a)(2) of the Securities Act, and Rule 506 promulgated under Regulation D of the Securities Act.

     

    Item 8.01 Other Events.

     

    On March 19, 2026, the Company issued a press release (the “Press Release”) announcing the signing of the Merger Agreement. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    2.1*   Agreement and Plan of Merger, dated as of March 18, 2026, by and among Datavault AI Inc., NYIAX, Inc. and DVLT Merger Sub Inc.
    99.1   Press Release.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    * Certain exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 19, 2026 DATAVAULT AI INC.
         
      By: /s/ Nathaniel Bradley
        Name: Nathaniel Bradley
        Title: Chief Executive Officer

     

     

     

    Get the next $DVLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVLT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DVLT
    SEC Filings

    View All

    Datavault AI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Datavault AI Inc. (0001682149) (Filer)

    3/19/26 8:12:57 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Datavault AI Inc. (0001682149) (Filer)

    3/19/26 7:45:19 AM ET
    $DVLT
    Semiconductors
    Technology

    SEC Form 10-K filed by Datavault AI Inc.

    10-K - Datavault AI Inc. (0001682149) (Filer)

    3/18/26 5:30:55 PM ET
    $DVLT
    Semiconductors
    Technology

    $DVLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DVLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets

    PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has made a $20 million strategic investment in Quantum Scan Holdings, Inc. ("Quantum Scan"), a breakthrough medical technology company, targeting trillion-dollar market of preventive diagnosis and prognosis of human diseases and illness. The investment is intended to support Quantum Scan's ongoing efforts to identify, develop,

    1/30/26 9:00:00 AM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Datavault AI Announces it will Exhibit at CES 2026 and Update Investors on Acoustics Division

    PHILADELPHIA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced it will exhibit its WiSA, ADIO, VerifyU, DVHolo, Events Citadel, Data Vault technology and event-based deployments at the Consumer Electronics Show (CES) in Las Vegas, Nevada from Jan. 6-9, 2026. Key Highlights in Datavault AI's Acoustics Division: Strong Intellectual Property growth in WiSA with nine new patents issued in 2025 for a total of 63 issued or filed, by Datavault AI. Increased demand for WiSA wireless audio modules reflects growing adoption of WiSA E acr

    12/30/25 7:05:16 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Inc. Announces Proposed Dividend of Warrants

    Record date for the proposed dividend of warrants will be on Jan. 7, 2026The warrants are expected to have a striking price of $5.00 per share of Datavault AI common stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar types of transactions)Each eligible participant is expected to be entitled to receive one (1) warrant to purchase one (1) share of Datavault AI common stock for every sixty (60) shares of Datavault AI common stock owned by such participant and is required to open a wallet with Datavault. PHILADELPHIA, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, cr

    12/29/25 7:55:00 AM ET
    $DVLT
    Semiconductors
    Technology

    Officer Mbugua Stanley sold $13,616 worth of shares (14,720 units at $0.93), decreasing direct ownership by 1% to 1,066,291 units (SEC Form 4)

    4 - Datavault AI Inc. (0001682149) (Issuer)

    12/30/25 5:36:10 PM ET
    $DVLT
    Semiconductors
    Technology

    Chief Executive Officer Bradley Nathaniel T sold $39,792 worth of shares (43,018 units at $0.93), decreasing direct ownership by 0.36% to 8,508,244 units (SEC Form 4)

    4 - Datavault AI Inc. (0001682149) (Issuer)

    12/30/25 5:35:23 PM ET
    $DVLT
    Semiconductors
    Technology

    Officer Moyer Brett sold $45,340 worth of shares (49,016 units at $0.93), decreasing direct ownership by 1% to 3,738,598 units (SEC Form 4)

    4 - Datavault AI Inc. (0001682149) (Issuer)

    12/30/25 5:34:12 PM ET
    $DVLT
    Semiconductors
    Technology

    $DVLT
    Leadership Updates

    Live Leadership Updates

    View All

    Datavault AI Appoints U.S. Navy Veteran Pete Scobell as Vice President, Global Security

    BEAVERTON, Ore., Oct. 21, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. (NASDAQ:DVLT), leading the way in AI data experience, valuation, and monetization, today announced the appointment of Pete Scobell as Vice President, Global Security. A decorated U.S. Navy SEAL veteran, Scobell will oversee Datavault AI's global security operations, risk management, and the execution of real-world asset logistics activity across all regions. Scobell's appointment comes as Datavault AI continues to advance its Anti-Stolen Valor initiative, first announced earlier this year, honoring military service, integrity, and accountability through a values-driven, data-backed ecosystem. The program reinf

    10/21/25 6:05:00 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Updates 4th Quarter, 2025 Outlook

    ·Company Incorporates Four Innovative Independent Data Exchanges with Expected Q4-25 Revenue Contribution ·Exchanges Expected to be Bolstered by Foundational Patents in the Tokenomics Economy ·Begins Enforcement Initiative with Top Tier Banks Led by Leading IP Firm BEAVERTON, Ore., Oct. 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (NASDAQ:DVLT), a pioneer in AI-driven tokenization and data monetization, today updated its 4th quarter of 2025 outlook and 2026 revenue guidance.  Highlights of the Company's Q4-25 outlook includes: ·Incorporating four innovative independent data exchanges ·Enhancing its patent portfolio, now exceeding 70 patents/filings, focused on c

    10/6/25 6:00:00 AM ET
    $DVLT
    Semiconductors
    Technology

    $DVLT
    Financials

    Live finance-specific insights

    View All

    Datavault AI Inc. Announces Board Approval of Dividend of Dream Bowl Meme Coin II to All Eligible Record Equity Holders of Datavault AI

    PHILADELPHIA, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today announced two major developments to enhance and elevate the profile of Dream Bowl XIV, scheduled for Jan. 11, 2026, at AT&T Stadium, of which the Company is a licensing partner and co-sponsor. First, Datavault AI, in collaboration with Dream Bowl XIV and NFL Alumni Health, proudly announces a strategic partnership supporting the launch of Dream Bowl Meme Coin II. This partnership underscores a shared commitment to advancing player health, wellness, and long-term care for former profession

    12/29/25 5:57:00 AM ET
    $DVLT
    Semiconductors
    Technology

    Datavault AI Inc. (NASDAQ: DVLT) Announces a Distribution Date of Dec. 24, 2025, for the Dream Bowl Meme Coin Tokens to All Eligible Record Equity Holders of Datavault AI and Holders of Common Stock of Scilex Holding Company

    PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the "Datavault Board") has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the "Meme Coin") to all eligible record equityholders of Datavault AI.  Dec. 24, 2025, will also be the distribution date for Datavault AI's voluntary distribution of Meme Coins to record holders of common stock of Scilex Holding Company (NASDAQ:SCLX), which is being made as a token of Datavault AI's appreciation for Scilex's relat

    12/11/25 4:05:00 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

    PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex's relationship with Datavault AI as a stockholder of Datavault A

    11/21/25 3:59:33 PM ET
    $DVLT
    $SCLX
    Semiconductors
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care